Trials / Completed
CompletedNCT02679079
Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 98 (actual)
- Sponsor
- Neurocrine Biosciences · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 6 weeks of treatment. This study will enroll approximately 90 male and female pediatric subjects clinically diagnosed with Tourette Syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NBI-98854 | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-03-23
- Primary completion
- 2017-04-14
- Completion
- 2017-04-14
- First posted
- 2016-02-10
- Last updated
- 2021-01-15
- Results posted
- 2021-01-15
Locations
44 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02679079. Inclusion in this directory is not an endorsement.